Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Omicron variant underscores need for new COVID vaccine candidates like IBIO-202

iBio (NYSE American:IBIO) updated its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron variant of SARS-CoV-2. According to the WHO, the Omicron variant has at least 30 mutations in...

November 29, 2021

Developments

Tetra Bio-Pharma posts positive initial data from ongoing Phase 2 trials of QIXLEEF

Tetra Bio-Pharma (TSX:TBP; OTCQB:TBPMF; FRA:JAM1) reported positive initial clinical data from its ongoing Phase 2 REBORN 1 and PLENITUDE trials of QIXLEEF for cancer pain. QIXLEEF is a botanical inhaled investigational...

November 29, 2021

Developments

POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center

POINT Biopharma Global (NASDAQ:PNT) entered into a technology license agreement with the Belgian Nuclear Research Center (SCK CEN) for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added...

November 24, 2021

Developments

111, Inc. Q3 net revenue climbs 41.6% to RMB 3.35 billion

111, Inc. (NASDAQ:YI), a leading tech-enabled healthcare platform in China, reported that third quarter net revenue rose 41.6% to RMB3.35 billion, or $519.3-milion (U.S.). In a statement, Junling Liu, co-founder...

November 19, 2021

Developments

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Oravax Medical, a unit of Oramed Pharmaceuticals (NASDAQ, TASE:ORMP), and Genomma Lab Internacional (BMV:LABB) formed of a 50/50 joint venture to develop and commercialize Oravax’s oral COVID-19 vaccine candidate...

November 18, 2021

Developments

Hepion, FibroFind report positive anti-cancer activity of CRV431 in liver cancer study

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. In addition...

November 16, 2021

Developments

iBio, UT Southwestern to investigate IBIO-100 in solid tumors

iBio (NYSEA:IBIO) and the University of Texas Southwestern Medical Center entered into a research collaboration to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program...

November 15, 2021

Developments

Posters on use of Altamira’s RNA delivery platforms presented at AHA scientific sessions

Altamira Therapeutics (NASDAQ:CYTO) announced the presentation of data at the American Heart Association scientific sessions from two studies by a research group at Washington University, St. Louis, on the use of the...

November 15, 2021

Developments

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection...

November 12, 2021

Developments

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Results from a study conducted by Dr. Philippe Gallay’s research group at The Scripps Research Institute examining the anti-tumor mechanism of Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate, CRV431, will be...

November 10, 2021

Developments

Cognetivity Neurosciences presents new results at AD conference

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF; FWB:1UB) presented significant new results demonstrating the capabilities of its Integrated Cognitive Assessment (ICA) platform at the Clinical Trials on Alzheimer’s...

November 9, 2021

Developments

Soricimed, Mount Allison University to collaborate on novel biopesticide solution

Closely-held Soricimed Biopharma and Dr. Vett Lloyd, a professor in the Biology Department at Mount Allison University and head of the Lloyd Tick Lab, are collaborating to design a species-specific, microbial...

November 9, 2021

Developments

BerGenBio presents bemcentinib data in NSCLC; receives FDA fast track

BerGenBio ASA (OSE:BGBIO) will deliver an e-poster presentation at the online Society for Immunotherapy of Cancer meeting with preclinical and clinical data suggesting that bemcentinib restored response to anti-PD-1...

November 9, 2021

Developments

POINT Biopharma, IONETIX in Ac-225 supply agreement

POINT Biopharma Global (NASDAQ:PNT) and IONETIX, a leading cyclotron technology and isotope manufacturing company, entered into a long-term supply agreement for actinium-225 (Ac-225) to support POINT’s validation, drug...

November 9, 2021

Developments

UNITY posts positive Phase 1 data in advanced vascular eye disease

UNITY Biotechnology (NASDAQ:UBX) announced positive 24-week data from its Phase 1 single ascending dose safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related...

November 9, 2021

Developments

RNADD in exclusive license for RNA-based molecular lateral flow assay technology

RNA Disease Diagnostics (RNADD) secured an exclusive global license to a rapid ribonucleic acid-based molecular lateral flow assay (LFA) technology jointly owned by the University of Maryland, Baltimore (UMB) and the...

November 9, 2021

Developments

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

In a presentation at the Society for Neuroscience 2021 meeting, Ben Land, Ph.D., research assistant professor at the University of Washington’s Department of Pharmacology, reported additional positive data from an...

November 8, 2021

Developments

iBio acquires FastPharming manufacturing facility

iBio (NYSEA:IBIO) purchased the manufacturing facility it previously operated under a lease from two affiliates of Eastern Capital and also acquired the approximate 30% equity interest in iBio CDMO held by the Eastern...

November 4, 2021

Developments

TransMedics posts positive results from randomized OCS DCD heart trial

TransMedics Group (NASDAQ:TMDX) reported positive topline results from its OCS donors after circulatory death (DCD) heart trial. The OCS DCD heart trial was designed as the first and only randomized trial to compare...

November 4, 2021

Developments

Activ Surgical completes first In-human study of surgical intelligence and sensing platform

Closely-held Activ Surgical, a digital surgery pioneer, completed of its first-in-human surgery clinical trial utilizing the company’s technology-as-a-service bundle: the ActivInsights augment reality (AR)-based...

November 3, 2021

Developments

Clene fails to meet endpoints in Phase 2 RESCUE-ALS clinical trial

Top-line data from Clene’s RESCUE-ALS, a Phase 2 clinical trial evaluating CNM-Au8 as a disease modifying treatment for people with early amyotrophic lateral sclerosis (ALS), failed to meet the primary or...

November 2, 2021

Developments

FDA grants Sio Gene fast track for gene therapy for GM2 gangliosidosis

Sio Gene Therapies (NASDAQ:SIOX) received fast track designation for AXO-AAV-GM2, an investigational gene therapy for the treatment of early infantile, late infantile, and juvenile-onset Tay-Sachs and Sandhoff disease...

November 1, 2021

Omicron variant underscores need for new COVID vaccine candidates like IBIO-202

Tetra Bio-Pharma posts positive initial data from ongoing Phase 2 trials of QIXLEEF

POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center

111, Inc. Q3 net revenue climbs 41.6% to RMB 3.35 billion

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Hepion, FibroFind report positive anti-cancer activity of CRV431 in liver cancer study

iBio, UT Southwestern to investigate IBIO-100 in solid tumors

Posters on use of Altamira’s RNA delivery platforms presented at AHA scientific sessions

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Cognetivity Neurosciences presents new results at AD conference

Soricimed, Mount Allison University to collaborate on novel biopesticide solution

BerGenBio presents bemcentinib data in NSCLC; receives FDA fast track

POINT Biopharma, IONETIX in Ac-225 supply agreement

UNITY posts positive Phase 1 data in advanced vascular eye disease

RNADD in exclusive license for RNA-based molecular lateral flow assay technology

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

iBio acquires FastPharming manufacturing facility

TransMedics posts positive results from randomized OCS DCD heart trial

Activ Surgical completes first In-human study of surgical intelligence and sensing platform

Clene fails to meet endpoints in Phase 2 RESCUE-ALS clinical trial

FDA grants Sio Gene fast track for gene therapy for GM2 gangliosidosis

General

More

Sign up for the BioTuesdays weekly newsletter